In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab.
about
Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.The relative biological effectiveness for carbon and oxygen ion beams using the raster-scanning technique in hepatocellular carcinoma cell lines.Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.Targeting the epidermal growth factor receptor in high-grade astrocytomas.Implications of EGFR PharmDx kit for cetuximab eligibility.Designer therapies for glioblastoma multiforme.Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.Molecularly targeted therapies for glioma.The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma.Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling.Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines.Epidermal growth factor receptor-targeted therapy.The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.Assessment of cetuximab efficacy by bioluminescence monitoring of intracranial glioblastoma xenograft in mouse.Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells.
P2860
Q33828459-46259820-35B5-4EE6-B858-5F0B9B080CC2Q34132872-8C11A210-DF21-4751-AE6F-1E777CD085E5Q35474588-1AC92ECD-FDA3-429F-A28F-77F4FC1AD14DQ35521316-D7DCAD6E-C831-4869-9547-B55DCA292F37Q36755432-5413A551-D5FD-4AF3-AB0D-0F7CB6073184Q36977690-00AA6ADB-8F21-47B8-8EE7-9C0E65217ED9Q37076172-A34F484E-5187-4C94-8AD2-925A53EC9C73Q37118974-922FD37F-8B1F-41E7-88AD-32D1AEE4E663Q37319650-1604FD2D-53DC-45E5-A2D5-0F50D14DCC5FQ37412251-D051A53A-39AA-4B96-8C47-2D796D9DF9C1Q37662768-0CA168C9-498F-46B0-A672-FEF52594622EQ39561175-949D4EB1-D57E-4BD3-876B-5C48B45E3814Q39700144-C1A5C4A5-F653-428B-8AFF-CFCC277D5B12Q39874006-EA7E7ECB-BDC8-4F24-B607-E8582717E89CQ40038133-D15C98FD-C53B-4B1F-9F5B-FD3FA27704C5Q42659700-C22AA1DC-D688-4EC5-94AB-93A6DCBA7076Q46043347-787F1C0D-09DC-4579-98D0-CF789FC9F695Q51060657-DA32EF54-579A-4ED8-A44C-F2DB50F0E687
P2860
In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
In vitro responsiveness of gli ...... tor inhibition with cetuximab.
@en
type
label
In vitro responsiveness of gli ...... tor inhibition with cetuximab.
@en
prefLabel
In vitro responsiveness of gli ...... tor inhibition with cetuximab.
@en
P2093
P50
P1476
In vitro responsiveness of gli ...... tor inhibition with cetuximab.
@en
P2093
Daniela Schulz-Ertner
Klaus-Josef Weber
Wilfried Roth
P304
P356
10.1016/J.IJROBP.2007.03.002
P407
P577
2007-07-01T00:00:00Z